Literature DB >> 11750939

GCV resistance due to the mutation A594P in the cytomegalovirus protein UL97 is partially reconstituted by a second mutation at D605E.

Osamu Ijichi1, Detlef Michel, Thomas Mertens, Koichiro Miyata, Yoshito Eizuru.   

Abstract

A ganciclovir (GCV)-resistant human cytomegalovirus (HCMV) was isolated from an AIDS patient. Molecular analysis of the HCMV UL97 gene revealed two point mutations, A594P and D605E, respectively. In order to evaluate quantitatively the impact of the individual mutations on GCV phosphorylation, recombinant vaccinia viruses (rVVs) were generated carrying either the two mutations (rVV-594/605) or only one mutation (rVV-594 or rVV-605, respectively). In cells infected with the rVV-594/605 double mutant, the GCV phosphorylation was decreased to 50% compared with the phosphorylation in cells infected with the rVV-UL97 wild-type. In cells infected with the rVV-594, however, the GCV phosphorylation was further decreased to 30%. Interestingly, the mutation D605E led to an even better GCV phosphorylation than that measured in cells infected with the rVV-UL97 wild type. These results were confirmed by plaque reduction assays, indicating that rVV-594 was more resistant to GCV than rVV-594/605. In contrast, rVV-605 was more sensitive to GCV than the rVV-UL97 wild type. Therefore, our results demonstrated for the first time that compensatory mutations can also occur in HCMV, as already shown for human immunodeficiency virus type 1.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11750939     DOI: 10.1016/s0166-3542(01)00202-9

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  12 in total

Review 1.  Human cytomegalovirus resistance to antiviral drugs.

Authors:  C Gilbert; G Boivin
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

2.  Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene.

Authors:  Sunwen Chou; Laura C Van Wechel; Heather M Lichy; Gail I Marousek
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

3.  Differentiation between polymorphisms and resistance-associated mutations in human cytomegalovirus DNA polymerase.

Authors:  Meike Chevillotte; Ina Ersing; Thomas Mertens; Jens von Einem
Journal:  Antimicrob Agents Chemother       Date:  2010-09-27       Impact factor: 5.191

4.  Improved detection of mutated human cytomegalovirus UL97 by pyrosequencing.

Authors:  Birgit Schindele; Luise Apelt; Jörg Hofmann; Andreas Nitsche; Detlef Michel; Sebastian Voigt; Thomas Mertens; Bernhard Ehlers
Journal:  Antimicrob Agents Chemother       Date:  2010-09-27       Impact factor: 5.191

5.  Novel real-time monitoring system for human cytomegalovirus-infected cells in vitro that uses a green fluorescent protein-PML-expressing cell line.

Authors:  T Ueno; Y Eizuru; H Katano; T Kurata; T Sata; S Irie; K Ogawa-Goto
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

Review 6.  Antiviral drug resistance of human cytomegalovirus.

Authors:  Nell S Lurain; Sunwen Chou
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

7.  Patient-Derived Cytomegaloviruses with Different Ganciclovir Sensitivities from UL97 Mutation Retain Their Replication Efficiency and Some Kinase Activity In Vitro.

Authors:  Diana D Wong; Wendy J van Zuylen; Stuart T Hamilton; Mirjam Steingruber; Eric Sonntag; Manfred Marschall; William D Rawlinson
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

8.  Prevalence of UL97 gene mutations and polymorphisms in cytomegalovirus infection in the colon associated with or without ulcerative colitis.

Authors:  Satoshi Tamura; Satoshi Osawa; Natsuki Ishida; Takahiro Miyazu; Shinya Tani; Mihoko Yamade; Moriya Iwaizumi; Yasushi Hamaya; Isao Kosugi; Takahisa Furuta; Ken Sugimoto
Journal:  Sci Rep       Date:  2021-07-01       Impact factor: 4.379

9.  Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient.

Authors:  Axel Schubert; Karoline Ehlert; Susanne Schuler-Luettmann; Eva Gentner; Thomas Mertens; Detlef Michel
Journal:  BMC Infect Dis       Date:  2013-07-19       Impact factor: 3.090

Review 10.  Antiviral Drug- and Multidrug Resistance in Cytomegalovirus Infected SCT Patients.

Authors:  Katharina Göhring; Klaus Hamprecht; Gerhard Jahn
Journal:  Comput Struct Biotechnol J       Date:  2015-02-10       Impact factor: 7.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.